Skip to main content

Aprecia

ApplicationBlue Ash, Ohio, USAFounded 2003· One of 686 Application companies tracked by AMPulse

Develops and manufactures 3D-printed pharmaceutical products using proprietary ZipDose® Technology for rapid-dissolving high-dose oral medications, with Spritam® as the first FDA-approved 3D-printed drug.

CEO / Founder
Owen Murray
Team Size
51-200
Stage
Active
Total Funding
$176M
Latest Round
Debt
Key Investors
Deerfield Management; Ben Franklin Technology Partners; Blue Chip Venture; JW Asset Management; Hercules Capital

Technology & Products

Key Products

Spritam® (first FDA-approved 3D-printed drug); CustomRelease (precision drug delivery systems)

Technological Advantage

Proprietary ZipDose® Technology allows for precise layer-by-layer deposition of active ingredients and excipients, enabling high-dose formulations with rapid disintegration; protected by 126 granted patents and 52 pending.

Patent position

Aprecia filed 10 patent families from 2022 to 2024, up from 5 in 2019 to 2021, a 100% rise, while tracked AM filings in the same patent offices fell 24%. AMPulse analysis

Filing momentum
10 families filed 2022–2024, 5 in 2019–2021 (+100%); all tracked AM filings in the same offices -24%
Filed in
US 53%EP 18%CN 16%WO 13%

38 AM patent families in total. Recent years are still being published, so read a filing change against the same-office figure.

Differentiation

Value Proposition

Enables production of high-dose (over 1000mg) medications that disintegrate rapidly in the mouth without water, improving patient compliance and addressing unmet treatment needs for conditions like epilepsy.

How They Differentiate

Holds first-mover advantage with FDA-approved commercial product (Spritam®) and extensive patent portfolio (126 granted), whereas competitors are in earlier stages or focus on different 3D printing processes like melt extrusion deposition.

Market & Competition

Target Customers

Branded, generic, OTC pharmaceutical, and nutraceutical partners

Industry Verticals

Pharmaceuticals; Healthcare; Medical

Competitors

BioZone Labs, LATITUDE Pharmaceuticals, Synthego

Growth & Milestones

Growth Metrics

Revenue estimated at $30.3 million with 63 employees; holds 126 granted patents and 52 pending.

Major Milestones

FDA approval of Spritam® in 2015 (first 3D-printed drug); Completion of $35 million financing led by Deerfield Management; Partnership with Battelle to scale 3D printed pharmaceutical manufacturing; Over 20 years of innovation in 3D printing pharma

Notable Customers

Prasco Laboratories

https://www.aprecia.com

AM patents

AM-relevant patents linked to this company.

Patents
45
Granted
21
Families
38

Leading domains: process (40), application (28), equipment (26)

Filings by year: 2024: 1 · 2023: 1 · 2022: 8 · 2021: 1 · 2020: 4 · 2019: 1

  1. METHOD AND SYSTEM FOR FORMING A DOSAGE FORM WITHIN A PACKAGING20220183986 · US
  2. THREE-DIMENSIONAL PRINTING SYSTEM AND EQUIPMENT ASSEMBLY03842215 · EP
  3. Three-dimensional Printing System and Equipment Assembly20160193787 · US
  4. Three-dimensional printing system and equipment assembly10118335 · US
  5. Three-dimensional printing system and equipment assembly11383440 · US

Funding rounds

  • Debt$20M2016-07-05Lead: Deerfield Management · Source: Tracxn
  • Series B2010-01-21Source: CB Insights

Why this company matters

AMPulse analysis, not a company disclosure

Aprecia Pharmaceuticals occupies a unique position as the first and only company to receive FDA approval for a 3D-printed pharmaceutical product. Its proprietary ZipDose technology addresses a specific gap in oral drug delivery: enabling high-dose medications, exceeding 1000 mg, that disintegrate rapidly in the mouth without water. This improves patient compliance for conditions such as epilepsy, where swallowing large tablets can be difficult.

The core technology is a binder jetting-like process that deposits active ingredients and excipients in precise layers, creating a porous structure that dissolves almost instantly. Aprecia's first commercial product, Spritam (levetiracetam), launched in 2015 for epilepsy. The company also offers CustomRelease precision drug delivery systems for partners. Its target customers include branded, generic, over-the-counter pharmaceutical, and nutraceutical firms, with Prasco Laboratories as a named partner.

Aprecia's strategic moat rests on its first-mover regulatory advantage and an extensive patent portfolio of 126 granted patents and 52 pending. Key partnerships with Battelle, Purdue University, and Merck KGaA support scale-up and development. The company has raised $176 million from investors including Deerfield Management and Hercules Capital. A key open question is whether the ZipDose platform can expand beyond epilepsy into other therapeutic areas and whether competitors using melt extrusion deposition will eventually achieve similar regulatory milestones.

With estimated revenue of $30.3 million and 63 employees, Aprecia remains a small but pivotal player in pharmaceutical 3D printing. Its CEO, Owen Murray, brings over 25 years of pharmaceutical operations experience from Recordati Rare Diseases and Cardinal Health.